Related Experiment Video
Updated: May 22, 2025
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
SPH3127 (Sitokiren), a Novel Renin Inhibitor, Suppresses Colitis Development in Mouse Models of Experimental Colitis
Weicheng Liu1, Lei Wang1, Caleb Muefong1
1Division of Biological Sciences, Department of Medicine, The University of Chicago, Chicago, IL, USA.
Background:
Emerging evidence suggests that the renin-angiotensin system plays an important role in the pathogenesis of inflammatory bowel disease, but few studies have directly assessed the therapeutic effect of renin inhibitors on colitis development.
Method:
Experimental colitis was induced in wild-type C57BL/6 mice and renin transgenic (RenTg) mice by 2,4,6-trinitrobenzene sulfonic acid (TNBS). Following intrarectal TNBS instillation, the mice were treated with SPH3127 (sitokiren), a small-molecule renin inhibitor, twice a day by intraperitoneal injection or oral gavage. The therapeutic effect of SPH3127 was evaluated by assessing clinical symptoms, histological injuries, and colonic mucosal inflammatory parameters in these mice.
Results:
SPH3127 treatment by either delivery route markedly attenuated body weight loss, reduced clinical severity, alleviated colon mucosal ulceration in both C57BL/6 and RenTg mice, and prevented animal death in the case of RenTg mice. SPH3127 treatment blocked the local induction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ, IL-17) and promoted the production of anti-inflammatory cytokine IL-10 in the colon. Fluorescence-activated cell sorting analysis revealed that SPH3127 substantially diminished the accumulation of TH1 and TH17 cells in the colonic mucosa and confirmed that SPH3127-induced IL-10 production from mucosal CD25+ T cells in the mice.
Conclusions:
These results demonstrate that SPH3127 is able to effectively block colitis development in mouse experimental colitis models. Its anti-colitogenic activity is achieved at least in part by suppressing mucosal TH1 and TH17 activation while promoting IL-10 production from mucosal CD25+ T cells, thus forming an anti-inflammatory environment in the colonic mucosa.
Insights
Renin inhibitor SPH3127 effectively treats experimental colitis in mice by reducing inflammation and promoting healing. This small molecule suppresses harmful immune responses while boosting beneficial anti-inflammatory cytokines in the colon.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- The renin-angiotensin system is implicated in inflammatory bowel disease pathogenesis.
- Therapeutic effects of renin inhibitors on colitis remain understudied.
Purpose of the Study:
- To assess the therapeutic efficacy of the renin inhibitor SPH3127 (sitokiren) in experimental colitis models.
- To investigate the underlying immunomodulatory mechanisms of SPH3127 in colitis.
Main Methods:
- Experimental colitis was induced in C57BL/6 and renin transgenic (RenTg) mice using TNBS.
- Mice received SPH3127 via intraperitoneal injection or oral gavage.
- Clinical, histological, and molecular inflammatory markers were analyzed.
Main Results:
- SPH3127 treatment significantly ameliorated colitis symptoms, including weight loss and ulceration, in both mouse strains.
- The drug suppressed pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ, IL-17) and increased anti-inflammatory IL-10.
- SPH3127 reduced TH1/TH17 cell accumulation and enhanced IL-10 production from CD25+ T cells in the colon.
Conclusions:
- SPH3127 demonstrates significant anti-colitogenic activity in mouse models.
- Its efficacy stems from suppressing TH1/TH17 responses and promoting IL-10 production, creating an anti-inflammatory colonic environment.
